Show simple item record

dc.contributor.authorResnick, Susan M.
dc.contributor.authorEspeland, Mark A.
dc.contributor.authorJaramillo, Sarah A.
dc.contributor.authorHirsch, C.
dc.contributor.authorStefanick, Marcia L.
dc.contributor.authorMurray, A. M.
dc.contributor.authorOckene, Judith K.
dc.contributor.authorDavatzikos, C.
dc.date2022-08-11T08:11:05.000
dc.date.accessioned2022-08-23T17:32:30Z
dc.date.available2022-08-23T17:32:30Z
dc.date.issued2009-01-13
dc.date.submitted2010-03-03
dc.identifier.citation<p>Neurology. 2009 Jan 13;72(2):135-42. <a href="http://dx.doi.org/10.1212/01.wnl.0000339037.76336.cf">Link to article on publisher's site</a></p>
dc.identifier.issn0028-3878 (Linking)
dc.identifier.doi10.1212/01.wnl.0000339037.76336.cf
dc.identifier.pmid19139364
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50964
dc.description.abstractOBJECTIVES: To determine whether menopausal hormone therapy (HT) affects regional brain volumes, including hippocampal and frontal regions. METHODS: Brain MRI scans were obtained in a subset of 1,403 women aged 71-89 years who participated in the Women's Health Initiative Memory Study (WHIMS). WHIMS was an ancillary study to the Women's Health Initiative, which consisted of two randomized, placebo-controlled trials: 0.625 mg conjugated equine estrogens (CEE) with or without 2.5 mg medroxyprogesterone acetate (MPA) in one daily tablet. Scans were performed, on average, 3.0 years post-trial for the CEE + MPA trial and 1.4 years post-trial for the CEE-Alone trial; average on-trial follow-up intervals were 4.0 years for CEE + MPA and 5.6 years for CEE-Alone. Total brain, ventricular, hippocampal, and frontal lobe volumes, adjusted for age, clinic site, estimated intracranial volume, and dementia risk factors, were the main outcome variables. RESULTS: Compared with placebo, covariate-adjusted mean frontal lobe volume was 2.37 cm(3) lower among women assigned to HT (p = 0.004), mean hippocampal volume was slightly (0.10 cm(3)) lower (p = 0.05), and differences in total brain volume approached significance (p = 0.07). Results were similar for CEE + MPA and CEE-Alone. HT-associated reductions in hippocampal volumes were greatest in women with the lowest baseline Modified Mini-Mental State Examination scores (scoresCONCLUSIONS: Conjugated equine estrogens with or without MPA are associated with greater brain atrophy among women aged 65 years and older; however, the adverse effects are most evident in women experiencing cognitive deficits before initiating hormone therapy.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19139364&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677493/
dc.subjectAge Factors
dc.subjectAged
dc.subjectAtrophy
dc.subjectBrain
dc.subjectCausality
dc.subjectCognition Disorders
dc.subjectDementia
dc.subjectEstrogen Replacement Therapy
dc.subjectEstrogens
dc.subjectEstrogens, Conjugated (USP)
dc.subjectFemale
dc.subjectHippocampus
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectNeuropsychological Tests
dc.subjectPrefrontal Cortex
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.subjectWomen's Studies
dc.titlePostmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study
dc.typeJournal Article
dc.source.journaltitleNeurology
dc.source.volume72
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/wfc_pp/494
dc.identifier.contextkey1192101
html.description.abstract<p>OBJECTIVES: To determine whether menopausal hormone therapy (HT) affects regional brain volumes, including hippocampal and frontal regions.</p> <p>METHODS: Brain MRI scans were obtained in a subset of 1,403 women aged 71-89 years who participated in the Women's Health Initiative Memory Study (WHIMS). WHIMS was an ancillary study to the Women's Health Initiative, which consisted of two randomized, placebo-controlled trials: 0.625 mg conjugated equine estrogens (CEE) with or without 2.5 mg medroxyprogesterone acetate (MPA) in one daily tablet. Scans were performed, on average, 3.0 years post-trial for the CEE + MPA trial and 1.4 years post-trial for the CEE-Alone trial; average on-trial follow-up intervals were 4.0 years for CEE + MPA and 5.6 years for CEE-Alone. Total brain, ventricular, hippocampal, and frontal lobe volumes, adjusted for age, clinic site, estimated intracranial volume, and dementia risk factors, were the main outcome variables.</p> <p>RESULTS: Compared with placebo, covariate-adjusted mean frontal lobe volume was 2.37 cm(3) lower among women assigned to HT (p = 0.004), mean hippocampal volume was slightly (0.10 cm(3)) lower (p = 0.05), and differences in total brain volume approached significance (p = 0.07). Results were similar for CEE + MPA and CEE-Alone. HT-associated reductions in hippocampal volumes were greatest in women with the lowest baseline Modified Mini-Mental State Examination scores (scoresCONCLUSIONS: Conjugated equine estrogens with or without MPA are associated with greater brain atrophy among women aged 65 years and older; however, the adverse effects are most evident in women experiencing cognitive deficits before initiating hormone therapy.</p>
dc.identifier.submissionpathwfc_pp/494
dc.contributor.departmentDepartment of Medicine, Division of Preventive and Behavioral Medicine
dc.source.pages135-42


This item appears in the following Collection(s)

Show simple item record